Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aims: To examine the albuminuria‐lowering effect of exenatide once weekly (EQW) compared with active glucose‐lowering comparators in patients with type 2 diabetes and elevated urinary albumin‐to‐creatinine ratio (uACR). Methods: Six randomized double‐blind and open‐label phase III studies were pooled in a post hoc , exploratory analysis to evaluate the efficacy and safety of EQW versus non‐glucagon‐like peptide‐1 receptor agonist comparators in patients with type 2 diabetes and baseline uACR ≥30 mg/g. Treatment groups were EQW versus all comparators pooled. Efficacy outcomes were percent change from baseline to week 26/28 in uACR and absolute change in glycated haemoglobin (HbA1c), systolic blood pressure (SBP), body weight and estimated glomerular filtration rate (eGFR). Results: Baseline characteristics were generally similar between the two treatment groups (EQW: N = 194, all comparators: N = 274). Relative to the comparator group, EQW changed albuminuria by −26.2% (95% confidence interval [CI] −39.5 to −10). Similar improvements were observed with EQW versus oral glucose‐lowering drugs (−29.6% [95% CI −47.6 to −5.3) or insulin (−23.8% [95% CI −41.8 to −0.2]). The effect of EQW on uACR was independent of baseline renin‐angiotensin system inhibitor usage. Adjusted mean decreases in HbA1c, SBP and body weight were more pronounced in the EQW versus the comparator group. Adjustment for changes in HbA1c, eGFR and SBP did not substantially affect the uACR‐lowering effect of EQW. When also adjusting for changes in body weight, the uACR‐lowering effect was reduced to (−13.0% [95% CI −29.9 to 7.8]). Conclusion: Exenatide once weekly reduced uACR in patients with type 2 diabetes and elevated albuminuria compared to commonly used glucose‐lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638 · cited 1×
“Other GLP-1RA trials have also suggested beneficial kidney effects, although the benefits were mainly driven by reductions in albuminuria.(7,8,19) Interestingly, the potential kidney benefits seem to be stronger in patients with established CKD.”
BackgroundDiamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Muskiet, M. H. A., Tonneijck, L., Huang, Y., Liu, M., Saremi, A., Heerspink, H. J. L., & van Raalte, D. H. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30268-7 · Cited by 259 · cited 1×
“Other GLP-1RA trials have also suggested beneficial kidney effects, although the benefits were mainly driven by reductions in albuminuria.(7,8,19) Interestingly, the potential kidney benefits seem to be stronger in patients with established CKD.”
BackgroundSelf-citation
Research works printed but not linked: 16
- 10.2174/1573399812666151223093841 · DOI · Paper page
- 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
- 10.2337/dc11-1107 · DOI · Paper page
- 10.1111/dom.12908 · DOI · Paper page
- 10.1016/j.clinthera.2012.07.007 · DOI
- 10.7326/0003-4819-130-6-199903160-00002 · DOI · Paper page
- 10.1053/j.ajkd.2008.12.034 · DOI · Paper page
- Perkovic V, 2019, FP482EGFR loss with glucagon‐like PEPTIDE‐1 (GLP‐1) analogue treatment: data from sustain 6 and leader, Nephrol Dial Transplant, 34
- 10.1016/S2213-8587(18)30104-9 · DOI · Paper page
- 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
- 10.1056/NEJMoa1515920 · DOI · Paper page
- 10.1056/NEJMoa1611925 · DOI · Paper page
- 10.1136/bmj.k5301 · DOI · Paper page
- 10.7326/0003-4819-144-1-200601030-00006 · DOI · Paper page
- 10.1155/2012/608397 · DOI
- 10.1016/S2213-8587(19)30080-4 · DOI
Cited by
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
“Furthermore, the change in the HbA1c value from baseline did not affect the result, suggesting that once-weekly exenatide reduced albuminuria independent of the glucose-lowering effect (Van Der Aart-Van Der Beek et al., 2020).”
Backgroundvan der Aart‐van der Beek, A. B., Clegg, L. E., Penland, R. C., Boulton, D. W., Sjöström, C. D., Mentz, R. J., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14175 · Cited by 37
Self-citationSivalingam, S., Wasehuus, V. S., Rotbain Curovic, V., Blond, M. B., Hansen, T. W., Persson, F., & Rossing, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15287 · Cited by 34
“20 Guidelines for the management of CKD in diabetes recommend SGLT2 inhibitors on top of RAAS hormone blockade for kidney and cardiovascular protection.”
BackgroundKang, C., Qiao, Q., Tong, Q., Bai, Q., Huang, C., Fan, R., Wang, H., Kaliannan, K., Wang, J., & Xu, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-99527-y · Cited by 14
Metadata
- Authors
- van der Aart ‐ van der Beek, A. B., van Raalte, D. H., Guja, C., Hoogenberg, K., Suchower, L. J., Hardy, E., Sjöström, C. D., & Heerspink, H. J. L.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-05-29
- Volume
- 22
- Issue
- 9
- Pages
- 1556-1566
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3018599559
- Cited by
- 28
- References
- 13
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. https://app.cochat.ai/papers/10.1111/dom.14067
- The paper
- van der Aart ‐ van der Beek, A. B., van Raalte, D. H., Guja, C., Hoogenberg, K., Suchower, L. J., Hardy, E., Sjöström, C. D., & Heerspink, H. J. L. (2020). Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.